Recent updates and developments in PET imaging of prostate cancer

Steven P. Rowe, Geoffrey B. Johnson, Martin G. Pomper, Michael A. Gorin, Spencer C. Behr

Research output: Contribution to journalArticle

Abstract

A number of positron emission tomography (PET) radiotracers have been developed to improve the sensitivity and specificity of imaging for prostate cancer. These radiotracers include the bone-seeking agent Na18F as well as more tumor-specific compounds such as 11C-choline and 18F-fluciclovine. In this review, we will discuss the advantages and disadvantages of these PET radiotracers for the imaging of men with prostate cancer across a range of clinical contexts. We will also touch upon radiotracers in late clinical development that have not gained regulatory approval, including those targeted against prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRPR).

Original languageEnglish (US)
JournalAbdominal Radiology
DOIs
StateAccepted/In press - Jan 1 2020

Keywords

  • Axumin
  • Bombesin
  • Choline
  • Fluciclovine
  • GRPR
  • PSMA

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology
  • Radiology Nuclear Medicine and imaging
  • Gastroenterology
  • Urology

Fingerprint Dive into the research topics of 'Recent updates and developments in PET imaging of prostate cancer'. Together they form a unique fingerprint.

  • Cite this

    Rowe, S. P., Johnson, G. B., Pomper, M. G., Gorin, M. A., & Behr, S. C. (Accepted/In press). Recent updates and developments in PET imaging of prostate cancer. Abdominal Radiology. https://doi.org/10.1007/s00261-020-02570-y